Search Within

Harold Varmus

  1. "Marc Ladanyi"
Formats
  1. Journal Article (6)
  2. Meeting Abstract (1)
Groups
  1. Department of Pathology and Laboratory Medicine (7)
  2. GSK Faculty (7)
  3. Human Oncology and Pathogenesis Program (7)
  4. Tow Center for Developmental Oncology (TCDO) (7)
  5. Department of Medicine (5)
  6. Solid Tumor Oncology Division (5)

More Groups

People
  1. Marc Ladanyi (7)
  2. Mark Kris (4)
  3. Gregory Riely (3)
  4. William Pao (3)
  5. Achim Jungbluth (2)
  6. Akihiko Yoshizawa (2)

More People

Years
  1. 2018 (1)
  2. 2017 (1)
  3. 2013 (1)
  4. 2010 (1)
  5. 2008 (1)
  6. 2007 (1)

More Years

Publications
  1. Nature (2)
  2. Journal of Clinical Oncology (1)
  3. Nature Genetics (1)
  4. PLoS ONE (1)
  5. PLos Medicine (1)
  6. Proceedings of the National Academy of Sciences of the United States of America (1)
Publishers
  1. Nature Publishing Group (3)
  2. Public Library of Science (2)
  3. American Society of Clinical Oncology (1)
  4. National Academy of Sciences (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
    Journal Article

    Fan, P. D.; Narzisi, G.; Jayaprakash, A. D.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Yu, H. A.; Jordan, E. J.; Paik, P. K.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2018)

    Fulltext@MSK | Save
  • YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing
    Meeting Abstract

    Fan, P. D.; Narzisi, G.; Jayaprakash, A.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Jordan, E.; Wang, L.; Jungbluth, A. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • DOK2 inhibits EGFR-mutated lung adenocarcinoma
    Journal Article

    Berger, A. H.; Chen, M.; Morotti, A.; Janas, J. A.; Niki, M.; Bronson, R. T.; Taylor, B. S.; Ladanyi, M.; Van Aelst, L.; Politi, K.; more...
    PLoS ONE (2013)

    Fulltext@MSK | Save
  • Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
    Journal Article

    Barretina, J.; Taylor, B. S.; Banerji, S.; Ramos, A. H.; Lagos-Quintana, M.; Decarolis, P. L.; Shah, K.; Socci, N. D.; Weir, B. A.; Ho, A.; more...
    Nature Genetics (2010)

    Fulltext@MSK | Save
  • Somatic mutations affect key pathways in lung adenocarcinoma
    Journal Article

    Ding, L.; Getz, G.; Wheeler, D. A.; Mardis, E. R.; McLellan, M. D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D. M.; Morgan, M. B.; more...
    Nature (2008)

    Fulltext@MSK | Save
  • Characterizing the cancer genome in lung adenocarcinoma
    Journal Article

    Weir, B. A.; Woo, M. S.; Getz, G.; Perner, S.; Ding, L.; Beroukhim, R.; Lin, W. M.; Province, M. A.; Kraja, A.; Johnson, L. A.; more...
    Nature (2007)

    Fulltext@MSK | Save
  • KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    Journal Article

    Pao, W.; Wang, T. Y.; Riely, G. J.; Miller, V. A.; Pan, Q.; Ladanyi, M.; Zakowski, M. F.; Heelan, R. T.; Kris, M. G.; Varmus, H. E.
    PLos Medicine (2005)

    Fulltext@MSK | Save